Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
GARDASIL®: Prophylactic Human Papillomavirus Vaccine Development - From Bench Top to Bed-side
Ist Teil von
Clinical pharmacology and therapeutics, 2007-02, Vol.81 (2), p.259-264
Ort / Verlag
New York, NY: Nature Publishing
Erscheinungsjahr
2007
Link zum Volltext
Quelle
MEDLINE
Beschreibungen/Notizen
GARDASIL® (Merck, Whitehouse Station, NJ) is a non‐infectious recombinant, quadrivalent vaccine prepared from the highly purified virus‐like particles (VLPs) of the major capsid proteins of human papillomavirus (HPV) types 6, 11, 16, and 18. GARDASIL® is the first vaccine approved for use in women aged 9–26 years for the prevention of cervical cancer and genital warts, as well as vulvar and vaginal precancerous lesions. This report describes some of the key preclinical efforts, achievements in pharmaceutical development, in vivo animal evaluation, and clinical trial data.
Clinical Pharmacology & Therapeutics (2007) 81, 259–264. doi:10.1038/sj.clpt.6100055